| Popis: |
Till now, the medicines approved for acute myeloid leukemia with internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) display not ideal efficacy. This study aimed to evaluate the effects of 15,16-dihydrotanshinone I on FLT3-ITD acute myeloid leukemia cells. The inhibitory effect of this compound against MV4-11 was determined using CCK-8 assay. Western blotting detecting caspase-3, PARP, and annexin V-APC/7-AAD was carried out. Activation of FLT3, STAT5, and Mcl-1 expression was analyzed by western blotting. The results showed that MV4-11 was sensitive toward dihydrotanshinone I in a dose-dependent manner (p |
